Almitas Capital LLC Reports 4.1% Stake in AN2 Therapeutics, Inc. (ANTX) via Amended 13G

Almitas Capital LLC filed a Schedule 13G/A on May 15, 2026, disclosing a position in AN2 Therapeutics, Inc. (ANTX). As of the event date on March 31, 2026, the investment firm reported beneficial ownership of 1,479,129 shares of Common Stock. This represents a 4.1% ownership stake in the company. The filing indicates that Almitas Capital LLC holds sole voting and dispositive power over all reported shares. Notably, this filing marks an increase from a previous reported ownership of 0.0%, according to the supplemental data provided. The firm, a Delaware-based investment adviser, certified that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Because the ownership level is now below the 5% threshold, the filing includes a checkmark indicating that the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities.